You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
高盛:降國藥(1099.HK)目標價至31.2港元 評級“中性”
格隆匯 10-30 15:39

高盛發表報告指,國藥(01099.HK)今年第三季銷售按年上升27.2%至1,100億元人民幣,純利則按年增長22.8%至16億元人民幣,表現均高於該行預期,相信兩票制改革後市場整合推動穩健的藥品分銷,以及醫療器械和零售藥房業務表現提升,為集團的新興增長動力。

該行上調對國藥今年至2021年的每股盈利預測分別0.1%、3.6%及5%,以反映醫療器械和零售藥房業務的銷售強勁提升。不過,由於長期市盈率預測由16.5倍降至10.2倍(為全球藥品分銷商今年的平均市盈率),高盛下調對集團股份目標價,由38.94港元降至31.2港元,評級維持“中性”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account